BIOGEN INC. is 6.0x more valuable than CRISPR Therapeutics AG by market capitalization ($28.73 B vs $4.77 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CRSP | BIIB |
|---|---|---|
| Market cap | $4.77 B | $28.73 B |
| US-listed rank | #1422 | #479 |
| Revenue (latest FY) | $3.51M | $9.89B |
| Net income (latest FY) | -$581.60M | $1.29B |
| Net margin | -16569.8% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 837 | 2,690 |
BIOGEN INC. is 6.0x more valuable than CRISPR Therapeutics AG by market capitalization ($28.73 B vs $4.77 B).
In their latest fiscal years, CRISPR Therapeutics AG reported $3.51M in revenue while BIOGEN INC. reported $9.89B.
Full pages: CRISPR Therapeutics AG and BIOGEN INC., or browse the full rankings.